Evotec schedules November 5 results: Evotec stock sits 60.33 percent below EUR 7.21

Published on 10/27/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec traded 340,427 shares on October 27. Evotec stock costs EUR 2.86 on October 27, 2026, down 0.35 percent versus Xetra close.

Reporting date and price position

Evotec is scheduled to publish its third-quarter and nine-month results on November 5, 2026.
Trading volume reached 340,427 shares on October 27, 2026.
Evotec stock costs EUR 2.86 at Lang & Schwarz, 0.35 percent below the EUR 2.87 Xetra close and 60.33 percent below its EUR 7.21 52-week high.

Evotec SE, DE0005664809, Illustration mit AI erstellt.

Evotec SE (ISIN DE0005664809) is scheduled to publish its third-quarter and nine-month results on November 5, 2026, according to StockTitan. At EUR 2.86, the stock stood 60.33 percent below its EUR 7.21 52-week high on October 27, 2026.

Results arrive November 5

The scheduled publication covers the third quarter and the first nine months of 2026. Evotec's preliminary nine-month revenue was EUR 465.0 million, while adjusted EBITDA was negative EUR 42.8 million, according to the October 14 filing carried by StockTitan. The company said the figures were above market expectations, while the variance mainly reflected the timing of consensus estimates.

Revenue guidance stays measurable

For fiscal year 2026, Evotec reaffirmed revenue guidance of EUR 570 million to EUR 610 million. Adjusted EBITDA guidance remained negative at EUR 70 million to EUR 105 million. The comparison matters because the nine-month revenue figure represents 76.23 percent of the lower end of that full-year revenue range.

Price position and valuation

Trading volume was 340,427 shares on October 27, 2026. The 52-week range was EUR 2.41 to EUR 7.21, placing the current price EUR 0.45 above the low and EUR 4.35 below the high. Evotec's market capitalization was EUR 509.7 million, and its price-to-earnings ratio was negative 2.59 on the same market snapshot.

Evotec operates in healthcare and drug manufacturing, developing drug candidates with pharmaceutical and biotechnology partners. Its investor-relations materials describe data-driven research, patient-based disease models and partnerships as central elements of the business model. The company employs 4,461 people.

Comparison with peers

Evotec: down 0.35 percent, price-to-earnings ratio negative 2.59, market capitalization EUR 509.7 million on October 27, 2026.

Bayer: up 0.77 percent, price-to-earnings ratio negative 26.08, market capitalization EUR 45.1 billion on October 27, 2026.

Lonza: up 0.13 percent, price-to-earnings ratio negative 410.06, market capitalization CHF 44.4 billion on October 27, 2026.

Evotec stock stays below its high

The scheduled results date gives investors the next fixed checkpoint, while the preliminary revenue figure leaves the full-year range as the central numerical comparison. Evotec stock was trading intraday at EUR 2.86 at Lang & Schwarz on October 27, 2026 at 5:31 p.m. CET, 0.35 percent below the Xetra close of October 27, 2026 (EUR 2.87). The further course of trading is shown by the continuously updated real-time quote of Evotec stock.